AbbVie, AstraZeneca lose appeal in Louisiana 340B contract pharmacy fight - endpoints.news
AbbVie and AstraZeneca's appeal regarding the Louisiana 340B contract pharmacy program has been denied, impacting their ability to limit contract pharmacy participation in the program.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 3, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug manufacturers and contract pharmacies involved in the 340B program. should confirm how it applies to their specific situation before acting. There is a time constraint attached: N/A. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The denial of the appeal means that the Louisiana 340B contract pharmacy program will continue to allow pharmacies to participate, affecting pricing and distribution strategies.
Who it affects
Branded drug manufacturers and contract pharmacies involved in the 340B program.
What you must do
Review and adjust pricing strategies and distribution agreements in light of the continued participation of contract pharmacies in the 340B program.
Deadline
N/A
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA approved cannabis: Why Schedule 3 means operators must prepare for pharmaceutical-grade MMJ now - MJBizDaily
- Update: State Disclosure and Transparency Laws for Pharmaceutical and Medical Device Manufacturers - McGuireWoods
- White House defends FDA's approval of second generic abortion pill amid GOP criticism - thenationaldesk.com
- FDA Launches Aggressive Crackdown on Direct-to-Consumer Drug Advertising It Considers Misleading - jdsupra.com
- FDA Introduces ‘PreCheck’ Plan to Strengthen US Drug Facilities - Bloomberg Law News